In a report published Monday, Credit Suisse analyst Christopher S. Parkinson initiated coverage on Evogene Ltd. EVGN with an Outperform rating and $25.00 price target.
In the report, Credit Suisse noted, “Initiating coverage with an Outperform rating and a $25 TP. We view EVGN as a best-in-class ag tech company well positioned to benefit from the secular need to enhance productivity per hectare. Their platform strength is evident by their ability to sign over 10 collaboration agreements with industry-leading seed/biotech companies (MON, DD, etc). The company's strong cash position and low cash burn rate should offer near-term support for its equity value, with several potential key positive catalysts on the horizon.”
Evogene Ltd. closed on Friday at $19.75.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in